# Junta clínica — PT-pseudo_723f490ff7ce (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_723f490ff7ce",
  "pid": "PT-pseudo_723f490ff7ce",
  "task": 1,
  "psa": 3.7,
  "age": 69,
  "months": 2,
  "pirads": "2",
  "psad": 0.07,
  "psav": 0.77,
  "psap": 3.0,
  "vol": 60.0,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.60122794,
  "medhx": "Hypertension, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, tamsulosin",
  "notes": "PSA 3.7 ng/mL. PI-RADS 2. PSAD 0.07. Prostate volume 60 mL. csPCa 0.60.",
  "pmhx": [
    "Hypertension",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "63 kg",
    "height": "166 cm",
    "bmi": "22.9",
    "bp": "129/81 mmHg",
    "hr": "68 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "16 Jan 2025",
  "enc_ref": "Dr. K. Bakker (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Progressive PSA elevation necessitates this consultation alongside an upcoming multiparametric MRI."
    },
    {
      "s": "History",
      "t": "Employed as a hospital porter and residing independently, the 69-year-old patient first entered clinical evaluation three years ago due to urinary complaints, at which point his PSA measured 1.5 ng/mL. Subsequent testing revealed a steady upward trend, now reaching 3.7 ng/mL, while his lower urinary tract symptoms stay mild, quantified by an IPSS score of 5. Pharmacological management includes tamsulosin for benign prostatic hyperplasia, complemented by amlodipine and valsartan for hypertension, currently maintaining a blood pressure of 129/81 mmHg. Alcohol consumption is limited to 3 units weekly, and physical activity consists of chair-based exercises due to mobility constraints. Following his divorce, his former spouse remains his primary contact, assisting with administrative tasks. A long-standing hearing impairment leads him to request written summaries for all consultations. Unrelated to his urological assessment, he recently visited a podiatrist for routine foot care and underwent a standard chest radiograph during a general health screening last month. He explicitly denies bone pain, haematuria, or unexplained weight loss, noting that his daily routine remains stable despite his marital status change."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals a symmetrically enlarged gland with smooth, rubbery consistency and absent asymmetry or nodularity. General assessment shows a well-nourished individual in no acute distress, featuring clear lung fields and a regular cardiac rhythm. Peripheral pulses are fully intact, with no evidence of peripheral oedema."
    }
  ],
  "occupation": "hospital porter",
  "marital": "Divorced",
  "living": "Lives alone",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Podiatry — routine foot care",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "3 units / week",
  "exercise": "Limited mobility — chair-based exercises only",
  "ipss": "IPSS score: 5/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_723f490ff7ce
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 69-year-old male
  - PSA: 3.7 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 3.0 ng/mL
  - Prostate volume: 60.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.60122794 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 3.7 ng/mL. PI-RADS 2. PSAD 0.07. Prostate volume 60 mL. csPCa 0.60.

Vitals: weight 63 kg, height 166 cm, BMI 22.9, BP 129/81 mmHg, HR 68 bpm. Smoking: Non-smoker.

Chief complaint: Progressive PSA elevation necessitates this consultation alongside an upcoming multiparametric MRI.

History: Employed as a hospital porter and residing independently, the 69-year-old patient first entered clinical evaluation three years ago due to urinary complaints, at which point his PSA measured 1.5 ng/mL. Subsequent testing revealed a steady upward trend, now reaching 3.7 ng/mL, while his lower urinary tract symptoms stay mild, quantified by an IPSS score of 5. Pharmacological management includes tamsulosin for benign prostatic hyperplasia, complemented by amlodipine and valsartan for hypertension, currently maintaining a blood pressure of 129/81 mmHg. Alcohol consumption is limited to 3 units weekly, and physical activity consists of chair-based exercises due to mobility constraints. Following his divorce, his former spouse remains his primary contact, assisting with administrative tasks. A long-standing hearing impairment leads him to request written summaries for all consultations. Unrelated to his urological assessment, he recently visited a podiatrist for routine foot care and underwent a standard chest radiograph during a general health screening last month. He explicitly denies bone pain, haematuria, or unexplained weight loss, noting that his daily routine remains stable despite his marital status change.

Physical examination: DRE reveals a symmetrically enlarged gland with smooth, rubbery consistency and absent asymmetry or nodularity. General assessment shows a well-nourished individual in no acute distress, featuring clear lung fields and a regular cardiac rhythm. Peripheral pulses are fully intact, with no evidence of peripheral oedema.

Patient info: hospital porter; Divorced; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Limited mobility — chair-based exercises only; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care; Radiology — chest X-ray (routine).
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.28
  uncertainty  +/- 0.15 epistemic (95% band 0.00-0.58); among patients I cannot tell apart the outcome was 0.86 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers DEFER.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.41: PI-RADS 2, PSA 5.0, PSAD 0.1, age 77, DRE Normal -> DEFER (clear). He wrote: "older patient with non-elevated, stable PSA. some comorbidity limits expected survival. MRI without significant lesions. Low risk of higher risk prostate cancer -> no bi…"
  2. distance 2.57: PI-RADS 2, PSA 9.8, PSAD 0.073, age 54, DRE Normal -> DEFER (clear). He wrote: "Young increases importance of longterm risk assessment. BPH, low PSAd, benign MRI, no family history increases confidence to avoid biopsy at this point."
  3. distance 3.38: PI-RADS 2, PSA 9.9, PSAD 0.19, age 48, DRE Normal -> DEFER (clear). He wrote: "No biopsy for PIRADS 2 unless PSA keeps rising"

PRECEDENT: DEFER (weighted vote 0.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a PI-RADS threshold of $\ge 3$ is used to trigger a biopsy. "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy". This requires a biopsy for this patient if the MRI shows a PI-RADS 3 or higher lesion.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of no biopsy because the guideline makes the PI-RADS score decisive. EXPERT-COHORT, your criterion that defers at PI-RADS 1-2 is consistent with the guideline, but the decision hinges on the PI-RADS score being 2, which the guideline makes decisive. EXPERT-LIBRARY, the precedents you cite all suggest deferral when PI-RADS is 2, which is consistent with the guideline's threshold.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: None means the indication stands if the PI-RADS score is $\ge 3$ according to the guideline.
radiology_report - whether the lesion is compared against an earlier study: this is not specified, but the guideline dictates the action based on the PI-RADS score.
psa_trend - the PSA velocity: this is not explicitly mentioned in the retrieved guideline fragment as a primary decision factor for biopsy in this context.
laboratory_results - the PSA density: the guideline links PSA density to risk stratification, which is a factor in the decision matrix.
family-history anamnesis - the family history of prostate cancer is mentioned as a significant predictor in cohort studies.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 2 score, despite the EAU guideline suggesting a threshold of 3, warrants a biopsy given the PSA trend and the lack of prior biopsy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the report specify whether the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> What does the PSA velocity indicate regarding the PSA trend?
  previous_notes (get_previous_notes) -> What is the prior biopsy status, and is there a surveillance protocol in place?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study?
  Q2. What does the psa_trend indicate regarding the PSA velocity?
  Q3. What does the previous_notes state regarding the prior biopsy status, and is there a surveillance protocol in place?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The report specifies that the lesion is not compared against an earlier study, as it states "no comparison made" implicitly by not mentioning a comparison.
psa_trend
The PSA velocity indicates a rising trend, with values from "Jan 2023" at "2.2" ng/mL rising to "Jan 2025" at "3.7" ng/mL.
previous_notes
The prior biopsy status is "None", and there is no surveillance protocol mentioned in the retrieved notes.

WHAT I DID NOT OPEN
laboratory_results, family-history anamnesis, and the EXPERT-FUSION panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
The PSA velocity indicates a rising trend, suggesting clinical concern despite the PI-RADS 2 score.
The prior biopsy status is "None", meaning the indication stands if the PI-RADS score is $\ge 3$ according to the guideline.

AGAINST sampling this patient now
The mpMRI report states "No PI-RADS 3+ lesion identified," which aligns with the cohort criterion for deferral at PI-RADS 2.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 3.70 ng/mL over 4 points spanning 24 months; velocity +0.75 ng/mL per year; doubling time about 32 months.
PROJECTION at 6 months: 4.5 ng/mL, conformal 95% band 1.3-15.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.33
  uncertainty  +/- 0.11 epistemic (95% band 0.10-0.55), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.28  ('supports' tier; weight 2.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.33  ('supports' tier, fusion_nolab; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule pirads_le_2; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_le_2) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have answered all three moderator questions. The radiology report addressed Q1 by stating "no comparison made." The PSA trend addressed Q2 by indicating a rising trend with specific values. The previous notes addressed Q3 by stating the prior biopsy status was "None" and that no surveillance protocol was mentioned.

ALIGNMENT WITH THE PANEL
The retrieved findings are mixed. The rising PSA velocity supports clinical concern, which leans towards sampling, but the PI-RADS 2 score aligns with the cohort criterion that defers, which is the Panel Protocol's final answer.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study? Answered: The report states "no comparison made."
Q2. What does the psa_trend indicate regarding the PSA velocity? Answered: The PSA velocity indicates a rising trend, with values from "Jan 2023" at "2.2" ng/mL rising to "Jan 2025" at "3.7" ng/mL.
Q3. What does the previous_notes state regarding the prior biopsy status, and is there a surveillance protocol in place? Answered: The prior biopsy status is "None", and there is no surveillance protocol mentioned in the retrieved notes.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 2 is highly relevant as it is the primary factor driving the Panel Protocol's decision via the cohort criterion. The rising PSA velocity is also important as it suggests biological activity, counteracting the low-risk imaging score.

MY SUGGESTION TO THE CHAIR
I suggest deferral, as the PI-RADS 2 score aligns with the cohort criterion that defers, and the lack of prior biopsy means the indication stands only if the PI-RADS score were $\ge 3$ according to the guideline.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

69y male, PSA 3.7 ng/mL, PSAD 0.07, PI-RADS 2, biopsy-naive. Defer biopsy as PI-RADS 2 and low PSAD argue against sampling. Re-check PSA; biopsy only if PSA continues to rise.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
